Clinical Trials
40
Active:0
Completed:28
Trial Phases
4 Phases
Phase 1:24
Phase 2:2
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (40 trials with phase data)• Click on a phase to view related trials
Phase 1
24 (60.0%)Phase 3
12 (30.0%)Not Applicable
2 (5.0%)Phase 2
2 (5.0%)A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A
Not Applicable
Not yet recruiting
- Conditions
- Mixed Dyslipidemia
- Interventions
- Drug: AD-117Drug: AD-117A
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT07152873
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, South Korea
A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
Not Applicable
Not yet recruiting
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- Drug: AD-116Drug: AD-1161
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT07103278
The Food Effect on PK Characteristics and Safety Profiles of PA-111
Phase 1
Not yet recruiting
- Conditions
- Mixed Dyslipidemia
- Interventions
- Drug: PA-111
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06976489
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A
Phase 1
Recruiting
- Conditions
- Mixed Dyslipidemia
- Interventions
- Drug: PA-111Drug: PA-111A
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06932705
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Phase 1
Not yet recruiting
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Drug: AD-120ADrug: AD-120
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT06916130
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next
News
No news found